Related Experiment Video

Updated: Sep 7, 2025

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

38.3K

RNA interference-based therapies for the control of atherosclerosis risk factors

Sanna Kettunen1, Anna-Kaisa Ruotsalainen1, Seppo Ylä-Herttuala1,2

  • 1A.I. Virtanen Institute, University of Eastern Finland.

Current Opinion in Cardiology
|June 22, 2022
PubMed
Abstract

Insights

RNA interference (RNAi) therapies show promise for treating atherosclerosis by targeting lipid metabolism and inflammation. Several RNAi drugs are approved, with more in clinical trials for cardiovascular and metabolic disorders.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Pharmacology

Background:

  • Atherosclerosis is a leading cause of global mortality, driven by arterial lipid accumulation and inflammation.
  • RNA interference (RNAi) technology offers a novel therapeutic approach for managing atherosclerosis risk factors.

Purpose of the Study:

  • To review the current status of RNA interference (RNAi) based therapies in clinical trials for atherosclerosis.
  • To highlight the potential of RNAi in treating atherosclerosis risk factors like hyperlipidemia and vascular inflammation.

Main Methods:

  • Review of current clinical trials investigating RNAi therapies for atherosclerosis.
  • Analysis of preclinical studies focusing on RNAi for vascular inflammation control.

Main Results:

  • RNAi therapies are targeting key genes in lipid metabolism, including PCSK9, ApoC-III, Lp(a), and ANGPTL3.
  • Successful plasma lipid lowering has been observed in multiple clinical trials.
  • Preclinical studies demonstrate promising results for RNAi in regulating vascular inflammation.

Conclusions:

  • RNAi-based therapies are rapidly advancing for atherosclerosis treatment, with several drugs approved and more in development.
  • The scope of RNAi therapies is expanding, offering encouraging prospects for cardiovascular and metabolic disorders.

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
29
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
73
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29